Qamar Farah Naz, Yousafzai Mohammad Tahir, Khaliq Asif, Karim Sultan, Memon Hina, Junejo Amber, Baig Inayat, Rahman Najeeb, Bhurgry Shafqat, Afroz Hina, Sami Uzma
Dept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Dept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan; Kirby Institute, University of New South Wales, Sydney, Australia.
Vaccine. 2020 Apr 23;38(19):3518-3523. doi: 10.1016/j.vaccine.2020.03.028. Epub 2020 Mar 20.
Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
巴基斯坦正面临着全球最大规模的广泛耐药性(XDR)伤寒疫情。2018年期间,在海得拉巴的高危地区为6个月至10岁的儿童开展了伤寒结合疫苗(Typbar-TCV®)接种活动。约20.7万名儿童接种了疫苗。在此,我们报告该活动期间的免疫接种后不良事件(AEFI)。活动采用了外展和固定中心策略。社区动员人员走访每户家庭进行名单登记,并动员有符合年龄儿童的家长。儿童接种疫苗后观察30分钟。采用双管齐下的策略来确定AEFI。为所有家长/监护人(n = 199861)提供了一个24/7热线电话,以便在免疫接种后的14天内报告AEFI。在第7天和第14天对一个按年龄分层的群体(n = 7139名儿童)进行主动随访,以确定AEFI。所有AEFI均由三名经过培训的医务人员进行检查。使用符合布莱顿协作标准且诊断确定性为3级的结构化问卷来记录AEFI。数据使用Microsoft Excel Office 365进行分析。总体而言,观察到499例AEFI(在主动随访的子集中有433例,通过热线自我报告的有66例)。与2至3岁的儿童相比,非常年幼的儿童(6至12个月龄组)的AEFI发生率显著更高(分别为0.54%和0.33%;p值<0.001)。发热是通过热线自我报告的最常见AEFI(38/199861 = 0.02%),也是在主动随访14天的子集中最常见的AEFI(206/7139 = 2.89%)。发热之后是局部反应原性,通过热线自我报告的为10/199861(0.01%),通过主动随访的为134/7139(1.88%)。未观察到严重的AEFI。在巴基斯坦海得拉巴的疫情期间,为6个月至10岁的儿童接种单剂量的Typbar-TCV是安全的。